Preparing for China · patient guide

Pathology review for lymphoma before treatment in China

A pathology review means a second group of pathologists re-examines your existing biopsy slides and blocks, not a new biopsy by default. For lymphoma it matters because the subtype and molecular findings steer which treatment is considered. In China the review is done by the receiving hospital's pathology service, and the lymphoma team decides whether the original diagnosis is confirmed, refined or needs more tissue.

Go to the practical guidance ↓
AI illustration: Silver suitcase standing outside a building entrance with a city skyline and traditional pagoda in the background.
AI-generated illustration for care planning; not a photograph of a real patient, clinician or hospital, and not a diagnostic image.
In this guide

Why lymphoma diagnosis is worth a second look before treatment

Lymphoma is not one disease. The World Health Organization classification separates many entities by the cell type involved, the tissue pattern and molecular features, and treatment differs substantially between them. A diagnosis built on a small or crushed sample, or one that predates newer molecular tests, can be incomplete even when the report looks definite.

That is the practical reason a review is requested before treatment rather than after. If the subtype changes, the treatment plan may change with it. If the review confirms the original diagnosis, you travel and start planning with more confidence. Either way, the decision about what the review means for your care belongs to the treating lymphoma team, not to the review report alone.

A review is also not a guarantee. Some samples are too small or too degraded for a confident answer, and the reviewing pathologist may say so. That is a useful result too, because it tells the clinical team that more tissue or different testing may be needed before a plan is fixed.

What the reviewing pathologists actually examine

The core of a pathology review is the original material: the glass slides stained from your biopsy and, where available, the paraffin blocks from which new sections can be cut. Pathologists re-read the slides, compare the pattern and cell appearance with the original description, and may run additional stains or molecular tests on the stored tissue.

For lymphoma, the questions a review commonly addresses include whether the architecture and cell population fit the reported entity, whether a low-grade and a high-grade component coexist, and whether markers such as those used to classify B-cell and T-cell lymphomas are adequately assessed. The exact panel is a clinical decision for the reviewing pathologist, based on what your original report already shows and what tissue remains.

Imaging and clinical history are not pathology, but they change how a report is read. The reviewing team benefits from knowing where the biopsy came from, what the scan showed and whether you have had prior treatment. Send the original pathology report in full, including any addenda, because the addendum often contains the molecular results that matter most.

Records to gather before you ask for a review

Start with the pathology file itself. You need the original signed report and any supplementary or molecular reports, the name and address of the laboratory that holds the slides and blocks, and a clear statement of how many blocks exist. Ask that laboratory whether it can release unstained slides or a tissue block for external review, and what it requires from you in writing.

Then gather the clinical file that gives the pathology context: imaging reports and the actual images if they can be shared, blood counts and relevant laboratory results, a treatment history if any, and a short summary of your main question. A concise summary helps the receiving team route the case correctly; a complete archive is not needed at first contact.

Cross-border shipment of human tissue is regulated, and the rules differ by country and by material. Do not assume slides can simply be couriered. Ask the releasing laboratory and the receiving hospital what documentation, packaging and permits they require, and confirm who is responsible at each end. If blocks cannot leave, unstained slides or a digital scan may be an alternative, but whether that is acceptable is the reviewing pathologist's call.

How the review fits with treatment planning in China

A pathology review is one input into a larger decision. The lymphoma team will also consider staging imaging, your general health, prior treatment and your own goals. A confirmed or revised pathology report does not by itself establish that a particular therapy is available, appropriate or funded for you, and it does not establish hospital acceptance.

It helps to separate three things that are easy to blur. The pathology review is a diagnostic opinion on tissue. The clinical consultation is where a hematologist or oncologist interprets that opinion for your case. Hospital acceptance and the treatment plan come after the hospital has assessed you. A review can support the second step without deciding the third.

Ask the receiving team, in writing, what the review will cover: rereading only, additional immunohistochemistry, molecular testing, or a formal second opinion letter. Ask who signs it and whether the report will state the level of diagnostic confidence. These details affect how much weight your treating clinician can place on it.

Related treatment reference

Questions to put to the treating team before you commit

The most useful questions are specific. Will the review be done on your existing slides, or does the team expect a new biopsy? If new tissue is needed, where and by whom? Which molecular tests does the team consider necessary to classify your lymphoma, and are they available on the stored material? What will the team do if the review is inconclusive?

Ask how the review result will be communicated and in what language, and whether a written report will be issued that your home clinicians can read. Ask what the review costs and what the quote covers, since pathology review, molecular testing and clinical consultation may be separate items. Ask the named provider for its written scope rather than relying on a general description.

It is also fair to ask how the review changes the timeline of your planning, without expecting a fixed number of days. The honest answer depends on tissue availability, testing and the hospital's own workflow, and the hospital should tell you what it can commit to.

Where ChinaSpecialistCare fits, and the limits

ChinaSpecialistCare is a non-clinical coordination service operated by Suzhou Fenglin International Travel Service Co., Ltd. We can help you organise the records, identify the questions to ask, and coordinate contact with a suitable hospital's pathology and lymphoma services. We do not read slides, issue pathology opinions or decide whether a diagnosis is correct.

An initial enquiry is free and asks only for a brief summary of your situation and your main question. You do not need to buy a proxy consultation to make that first contact, and a proxy consultation is optional rather than a prerequisite for care. Hospital and provider charges are separate from any coordination fee, and the hospital decides whether it will accept your case.

A practical next step: gather your original pathology report with any addenda, note where the slides and blocks are held, and send a short summary through the enquiry form. From there we can help you frame the specific questions for the reviewing pathologists and the lymphoma team, so that the review answers the decision you actually face.

Sources & scope of this guide

References and official service information relevant to this guide.

  1. Related treatment reference
  2. Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®) - NCI
  3. Hodgkin Lymphoma Treatment (PDQ®) - NCI
  4. Aggressive B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®) - NCI
  5. Mantle Cell Lymphoma Treatment (PDQ®) - NCI
  6. Peripheral T-Cell Non-Hodgkin Lymphoma Treatment (PDQ®) - NCI

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.